Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A ...

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...

Lynk Pharmaceuticals Co., Ltd. ('Lynk Pharmaceuticals'), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, today announced a significant clinical ...

INGELHEIM, Germany & SINGAPORE--(BUSINESS WIRE)--Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 ...

(A) Schematic illustration of the synthesis process for a carbon material with controlled mesoscale porosity. (B) External view of the 1-Wh-class stacked lithium-air battery fabricated in this study.

BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...